M. F. Dias, K. Joo, J. A. Kemp, S. L. Fialho, A. Da-silva-cunha et al., Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives, Prog Retin Eye Res, vol.63, pp.107-131, 2018.

K. Cholkar, S. P. Patel, A. D. Vadlapudi, and A. K. Mitra, Novel strategies for anterior segment ocular drug delivery, J Ocul Pharmacol Ther, vol.29, pp.106-123, 2013.

A. K. Hoskin, D. A. Mackey, L. Keay, R. Agrawal, and S. Watson, Eye Injuries across history and the evolution of eye protection, Acta Ophthalmol, vol.97, pp.637-643, 2019.

S. R. Flaxman, R. R. Bourne, S. Resnikoff, P. Ackland, T. Braithwaite et al., Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. The Lancet Global Health, vol.5, pp.1221-1234, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02628834

A. Sabzevari, K. Adibkia, H. Hashemi, A. Hedayatfar, N. Mohsenzadeh et al., Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies, Eur J Pharm Biopharm, vol.84, pp.63-71, 2013.

J. S. Pober and W. C. Sessa, Evolving functions of endothelial cells in inflammation, Nat. Rev. Immunol, vol.7, pp.803-815, 2007.

G. Yogalingam, A. R. Lee, D. S. Mackenzie, T. J. Maures, A. Rafalko et al., Cellular Uptake and Delivery of Myeloperoxidase to Lysosomes Promote Lipofuscin Degradation and Lysosomal Stress in Retinal Cells, J Biol Chem, vol.292, pp.4255-4265, 2017.

R. Medzhitov, Origin and physiological roles of inflammation, Nature, vol.454, pp.428-435, 2008.

C. Nathan, Points of control in inflammation, Nature, vol.420, pp.846-852, 2002.

. References-nanosuspensions-for-oph1, M. Ahuja, A. S. Dhake, S. K. Sharma, and D. K. Majumdar, Topical ocular delivery of NSAIDs, AAPS J, vol.10, pp.229-241, 2008.

F. Behar-cohen, Towards an Optimized Use of Ocular Corticosteroids: EURETINA Award Lecture, Ophthalmologica, vol.240, pp.111-119, 2017.

R. Schalnus, Topical nonsteroidal anti-inflammatory therapy in ophthalmology, Ophthalmol. J. Int. Ophtalmol. Int. J. Ophthalmol. Z. Augenheilkd, vol.217, pp.89-98, 2003.

D. J. Wilson, S. M. Schutte, and S. R. Abel, Comparing the Efficacy of Ophthalmic NSAIDs in Common Indications: A Literature Review to Support Cost-effective Prescribing, Ann. Pharmacother, vol.49, pp.727-734, 2015.

P. K. Suresh and A. K. Sah, Patent perspectives for corticosteroids based ophthalmic therapeutics. Recent Pat, Drug Deliv. Formul, vol.8, pp.206-223, 2014.

U. B. Kompella, R. S. Kadam, and V. H. Lee, Recent advances in ophthalmic drug delivery, Ther. Deliv, vol.1, pp.435-456, 2010.

S. Gause, K. Hsu, C. Shafor, P. Dixon, K. C. Powell et al., Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses, Adv. Colloid Interface Sci, vol.233, pp.139-154, 2016.

F. E. Koç and M. Senel, Solubility enhancement of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) using polypolypropylene oxide core PAMAM dendrimers, Int. J. Pharm, vol.451, pp.18-22, 2013.

M. D. Moya-ortega, M. Messner, P. Jansook, T. T. Nielsen, V. Wintgens et al., Drug loading in cyclodextrin polymers: dexamethasone model drug, J. Incl. Phenom. Macrocycl. Chem, vol.69, pp.377-382, 2011.

R. S. Hoffman, R. Braga-mele, K. Donaldson, G. Emerick, B. Henderson et al., Cataract surgery and nonsteroidal antiinflammatory drugs, J. Cataract Refract. Surg, vol.42, pp.1368-1379, 2016.

R. K. Thomas and R. Melton, Unleash the power of corticosteroids, Rev. Optom, pp.26-32, 2016.

X. Liu, S. Wang, A. A. Kao, and Q. Long, The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes, Cornea, vol.31, pp.1235-1239, 2012.

H. He, Z. Liu, Z. Lin, X. Liu, H. He et al., Therapeutic effects of Pyranoprofen on the mouse dry eye induced by topical medication of Benzalkonium Chloride

, Zhonghua Yan Ke Za Zhi Chin. J. Ophthalmol, vol.48, pp.33-40, 2012.

P. Aragona, R. Spinella, L. Rania, E. Postorino, M. S. Sommario et al., Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome, Eur. J. Ophthalmol, vol.23, pp.368-376, 2013.

L. Mulki and C. S. Foster, Difluprednate for inflammatory eye disorders, Drugs Today Barc. Spain, vol.47, pp.327-333, 1998.

M. A. Slabaugh, E. Herlihy, S. Ongchin, and R. N. Van-gelder, Efficacy and potential complications of difluprednate use for pediatric uveitis, Am. J. Ophthalmol, vol.153, pp.932-938, 2012.

M. J. Coffey, H. H. Decory, and S. S. Lane, Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop, Clin. Ophthalmol. Auckl. NZ, vol.7, pp.299-312, 2013.

M. Ahuja, A. S. Dhake, S. K. Sharma, and D. K. Majumdar, Topical ocular delivery of NSAIDs, AAPS J, vol.10, pp.229-241, 2008.

J. D. Sheppard, T. L. Comstock, and M. E. Cavet, Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure, Adv. Ther, vol.33, pp.532-552, 2016.

J. L. Davis, B. C. Gilger, and M. R. Robinson, Novel approaches to ocular drug delivery, Curr. Opin. Mol. Ther, vol.6, pp.195-205, 2004.

T. L. Ke, G. Graff, J. M. Spellman, and J. M. Yanni, Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers, Inflammation, vol.24, pp.371-384, 2000.

R. Lindstrom and T. Kim, Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac, Curr. Med. Res. Opin, vol.22, pp.397-404, 2006.

K. Cholkar, S. P. Patel, A. D. Vadlapudi, and A. K. Mitra, Novel strategies for anterior segment ocular drug delivery, J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther, vol.29, pp.106-123, 2013.

P. Taskar, A. Tatke, and S. Majumdar, Advances in the use of prodrugs for drug delivery to the eye, Expert Opin. Drug Deliv, vol.14, pp.49-63, 2017.

V. Gote, S. Sikder, J. Sicotte, and D. Pal, Ocular Drug Delivery: Present Innovations and Future Challenges, J. Pharmacol. Exp. Ther, vol.370, pp.602-624, 2019.

D. Achouri, K. Alhanout, P. Piccerelle, and V. Andrieu, Recent advances in ocular drug delivery, Drug Dev. Ind. Pharm, vol.39, pp.1599-1617, 2013.

N. R. Acharya, V. M. Tham, E. Esterberg, D. S. Borkar, J. V. Parker et al., Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study, JAMA Ophthalmol, vol.131, pp.1405-1412, 2013.

U. B. Kompella, R. S. Kadam, and V. H. Lee, Recent advances in ophthalmic drug delivery, Ther Deliv, vol.1, pp.435-456, 2010.

S. Gause, K. Hsu, C. Shafor, P. Dixon, K. C. Powell et al., Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses, Adv Colloid Interface Sci, vol.233, pp.139-154, 2016.

A. Ludwig, The use of mucoadhesive polymers in ocular drug delivery, Adv Drug Deliv Rev, vol.57, pp.1595-1639, 2005.

K. Edsman and H. Hägerström, Pharmaceutical applications of mucoadhesion for the non-oral routes, J Pharm Pharmacol, vol.57, pp.3-22, 2005.

K. Kesavan, S. Kant, P. N. Singh, and J. K. Pandit, Effect of hydroxypropyl-?-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel, Curr Eye Res, vol.36, pp.918-929, 2011.

K. M. Saari, L. Nelimarkka, V. Ahola, T. Loftsson, and E. Stefánsson, Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation, Graefes Arch Clin Exp Ophthalmol, vol.244, pp.620-626, 2006.

A. Ohira, K. Hara, G. Jóhannesson, M. Tanito, G. M. Ásgrímsdóttir et al., Topical dexamethasone ?-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema, Act Ophthalmol, vol.93, pp.610-615, 2015.

C. Stahn, M. Löwenberg, D. W. Hommes, and F. Buttgereit, Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists, Mol Cell Endocrinol, vol.275, pp.71-78, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00531935

F. E. Koç and M. Senel, Solubility enhancement of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) using polypolypropylene oxide core PAMAM dendrimers, Int J Pharm, vol.451, pp.18-22, 2013.

M. D. Moya-ortega, M. Messner, P. Jansook, T. T. Nielsen, V. Wintgens et al., Drug loading in cyclodextrin polymers: dexamethasone model drug, J Incl Phenom Macrocycl Chem, vol.69, pp.377-382, 2011.

A. Usayapant, A. H. Karara, and M. M. Narurkar, Effect of 2-hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate, Pharm Res, vol.8, pp.1495-1499, 1991.

H. M. Leibowitz, A. Kupferman, R. H. Stewart, and R. L. Kimbrough, Evaluation of dexamethasone acetate as a topical ophthalmic formulation, Am J Ophthalmol, vol.86, pp.418-423, 1978.

S. Göktürk, E. Çal??kan, R. Y. Talman, and U. Var, A Study on Solubilization of Poorly Soluble Drugs by Cyclodextrins and Micelles: Complexation and Binding Characteristics of Sulfamethoxazole and Trimethoprim, ScientificWorldJournal, p.718791, 2012.

P. Jansook, N. Ogawa, and T. Loftsson, Cyclodextrins: structure, physicochemical properties and pharmaceutical applications, Int J Pharm, vol.535, pp.272-284, 2018.

C. Muankaew and T. Loftsson, Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery, Basic Clin Pharmacol Toxicol, vol.122, pp.46-55, 2018.

M. C. Urban, R. M. Mainardes, and M. P. Gremião, Development and validation of HPLC method for analysis of dexamethasone acetate in microemulsions, Braz J Pharm Sci, vol.45, pp.87-92, 2009.

T. Higuchi and K. A. Connors, Phase-solubility techniques, Advanced in Analytical Chemistry and Instrumentation, pp.117-212, 1965.

P. Jansook and T. Loftsson, gammaCD/HPgammaCD: synergistic solubilization, Int J Pharm, vol.363, pp.217-219, 2008.

T. Loftsson, D. Hreinsdóttir, and M. Másson, Evaluation of cyclodextrin solubilization of drugs, Int J Pharm, vol.302, pp.18-28, 2005.

C. Ravelet, A. Geze, A. Villet, C. Grosset, A. Ravel et al., Chromatographic determination of the association constants between nimesulide and native and modified beta-cyclodextrins, J Pharm Biomed Anal, vol.29, pp.425-430, 2002.

E. Peyrin, Y. C. Guillaume, C. Grosset, A. Villet, A. Ravel et al., Sucrose effect on reversed-phase liquid chromatography solute retention, Anal Chim Acta, vol.428, pp.83-88, 2001.

V. Chédru-legros, M. Fines-guyon, A. Chérel, A. Perdriel, F. Albessard et al.,

, J Fr Ophtalmol, vol.30, pp.807-813, 2007.

G. E. Box, W. G. Hunter, and J. S. Hunter, Statistics for experimenters: an introduction to design, data analysis, and model building; Wiley-Probability and mathematical statistics, 1978.

Y. Yin and C. W. Carter, Incomplete factorial and response surface methods in experimental design: yield optimization of tRNA(Trp) from in vitro T7 RNA polymerase transcription, Nucleic Acids Res, vol.24, pp.1279-1286, 1996.

S. Umar, N. Bakhary, and A. R. Abidin, Response surface methodology for damage detection using frequency and mode shape, Measurement, vol.115, pp.258-268, 2018.

R. F. Vianna, M. V. Bentley, G. Ribeiro, F. S. Carvalho, A. F. Neto et al., Formation of cyclodextrin inclusion complexes with corticosteroids: their characterization and stability, Int J Pharm, vol.167, pp.205-213, 1998.

F. Djedaïni and B. Perly, Nuclear Magnetic Resonance Investigation of the Stoichiometrics in ?-Cyclodextrin:Steroid Inclusion Complexes, J Pharm Sci, vol.80, pp.1157-1161, 1991.

K. G. Flood, E. R. Reynolds, and N. H. Snow, Characterization of inclusion complexes of betamethasone-related steroids with cyclodextrins using high-performance liquid chromatography, J Chromatogr A, vol.903, pp.49-65, 2000.

E. Stefánsson and T. Loftsson, Cyclodextrins in Eye Drop Formulations, J Incl Phenom Macrocycl Chem, vol.44, pp.23-27, 2002.

Y. W. Chen, H. V. Lee, and S. B. Hamid, Investigation of optimal conditions for production of highly crystalline nanocellulose with increased yield via novel Cr(III)-catalyzed hydrolysis: Response surface methodology, Carbohydrate Polymers, vol.178, pp.57-68, 2017.

G. Derringer and R. Suich, Simultaneous Optimization of Several Response Variables, J Qual Technol, vol.12, pp.214-219, 1980.

J. A. Nelder and R. Mead, A simplex method for function minimization, Computer Journal, vol.7, pp.308-313, 1965.

W. H. Press, B. P. Flannery, S. A. Teukolsky, and W. T. Vetterling, Numerical recipes in Pascal: the art of scientific computing

. England, , 1989.

H. Bothner, T. Waaler, and O. Wik, Rheological Characterization of Tear Substitutes, Drug Dev Ind Pharm, vol.16, pp.755-768, 1990.

A. Ohira, K. Hara, G. Jóhannesson, M. Tanito, G. M. Ásgrímsdóttir et al., Topical dexamethasone ?-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema, Act Ophthalmol, vol.93, pp.610-615, 2015.

R. Villanueva, J. Villanueva, L. Guzmán-navarro, and M. , Pharmaceutical technology can turn a traditional drug, dexamethasone into a first-line ocular medicine. A global perspective and future trends, Int J Pharm, vol.516, pp.342-351, 2017.

Q. Pan, Q. Xu, N. J. Boylan, N. W. Lamb, D. G. Emmert et al., Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats, J Control Release, vol.201, pp.32-40, 2015.

P. M. Hughes, O. Olejnik, J. Chang-lin, and C. G. Wilson, Topical and systemic drug delivery to the posterior segments, Adv. Drug Deliv. Rev, vol.57, pp.2010-2032, 2005.

A. Usayapant, A. H. Karara, and M. M. Narurkar, Effect of 2-hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate, Pharm Res, vol.8, pp.1495-1499, 1991.

H. M. Leibowitz, A. Kupferman, R. H. Stewart, and R. L. Kimbrough, Evaluation of dexamethasone acetate as a topical ophthalmic formulation, Am J Ophthalmol, vol.86, pp.418-423, 1978.

R. Mazet, L. Choisnard, D. Levilly, D. Wouessidjewe, and A. Gèze, Investigation of Combined Cyclodextrin and Hydrogel Formulation for Ocular Delivery of Dexamethasone Acetate by Means of Experimental Designs, Pharmaceutics, p.10, 2018.

M. Guillon, C. Maissa, and S. Ho, Evaluation of the effects on conjunctival tissues of Optive eyedrops over one month usage, Cont Lens Anterior Eye, vol.33, pp.93-99, 2010.

B. Chatterjee, N. Amalina, P. Sengupta, and U. Kumar-mandal, Mucoadhesive polymers and their mode of action: A recent update, Journal of Applied Pharmaceutical Science, vol.7, pp.195-203, 2017.

D. Achouri, K. Alhanout, P. Piccerelle, and V. Andrieu, Recent advances in ocular drug delivery, Drug Dev Ind Pharm, vol.39, pp.1599-1617, 2013.

H. J. Oh, Z. Li, S. Park, and K. C. Yoon, Effect of hypotonic 0.18% sodium hyaluronate eyedrops on inflammation of the ocular surface in experimental dry eye, J Ocul Pharmacol Ther, vol.30, pp.533-542, 2014.

M. C. Urban, R. M. Mainardes, and M. P. Gremião, Development and validation of HPLC method for analysis of dexamethasone acetate in microemulsions, Braz J Pharm Sci, vol.45, pp.87-92, 2009.

, International Conference on Harmonisation -Validation of Analytical Procedures: Text and Methodology Q2(R1), 2005.

J. S. Space, A. M. Opio, B. Nickerson, H. Jiang, M. Dumont et al., Validation of a dissolution method with HPLC analysis for lasofoxifene tartrate low dose tablets, Journal of Pharmaceutical and Biomedical Analysis, vol.44, pp.1064-1071, 2007.

, Evaluation and Research Group on Protection in Controlled Atmosphere (GERPAC) French Society of Clinical Pharmacy (SFPC) Evaluation and Research Group on Protection in Controlled Atmosphere (GERPAC) Methodological guidelines for stability studies of pharmaceutical preparations, French Society of Clinical Pharmacy

A. Graça, L. M. Gonçalves, S. Raposo, H. M. Ribeiro, and J. Marto, Useful In Vitro Techniques to Evaluate the Mucoadhesive Properties of Hyaluronic Acid-Based Ocular Delivery Systems, Pharmaceutics, p.10, 2018.

M. M. Silva, R. Calado, J. Marto, A. Bettencourt, A. J. Almeida et al., Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration, p.15, 2017.

S. B. Da-silva, D. Ferreira, M. Pintado, and B. Sarmento, Chitosan-based nanoparticles for rosmarinic acid ocular delivery--In vitro tests, Int. J. Biol. Macromol, vol.84, pp.112-120, 2016.

S. Rönkkö, K. Vellonen, K. Järvinen, E. Toropainen, and A. Urtti, Human corneal cell culture models for drug toxicity studies, Drug Deliv Transl Res, vol.6, pp.660-675, 2016.

Y. Wen, J. Ban, Z. Mo, Y. Zhang, P. An et al., A potential nanoparticle-loaded in situ gel for enhanced and sustained ophthalmic delivery of dexamethasone, Nanotechnology, vol.29, p.425101, 2018.

N. R. Council, Guide for the Care and Use of Laboratory Animals: Eighth Edition, 2010.

, Committee for the Update of the Guide for the Care and Use of Laboratory Animals Guide for the Care and Use of Laboratory Animals; The National Academies Collection: Reports funded by National Institutes of Health, 2011.

Y. Zhang, M. Huo, J. Zhou, S. Xie, and . Pksolver, An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel, Computer Methods and Programs in Biomedicine, vol.99, pp.306-314, 2010.

, European Phramacopoeia; 9, 2019.

G. K. Mcevoy, System Pharmacists AHFS Drug information, 2007.

, Bethesda, Md, 2007.

I. Zaki, P. Fitzgerald, J. G. Hardy, and C. G. Wilson, A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man, J. Pharm. Pharmacol, vol.38, pp.463-466, 1986.

G. R. Snibson, J. L. Greaves, N. D. Soper, J. I. Prydal, C. G. Wilson et al., Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy, Eye (Lond), vol.1990, issue.4, pp.594-602

R. Salzillo, C. Schiraldi, L. Corsuto, A. D'agostino, R. Filosa et al., Optimization of hyaluronan-based eye drop formulations, Carbohydrate Polymers, vol.153, pp.275-283, 2016.

A. Franck, Understanding Rheology of Structured Fluids, TA instruments, pp.1-11, 2004.

F. Madsen, K. Eberth, and J. D. Smart, A rheological examination of the mucoadhesive/mucus interaction: the effect of mucoadhesive type and concentration, J Control Release, vol.50, pp.167-178, 1998.

A. Ludwig, The use of mucoadhesive polymers in ocular drug delivery, Adv Drug Deliv Rev, vol.57, pp.1595-1639, 2005.

, OECD Guideline for the testing of chemicals -Short time exposure in vitro test method, p.19, 2018.

G. Piel, M. Piette, V. Barillaro, D. Castagne, B. Evrard et al., Study of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomes, International Journal of Pharmaceutics, vol.338, pp.35-42, 2007.

A. Fernández-ferreiro, N. Fernández-bargiela, M. S. Varela, M. G. Martínez, M. Pardo et al., Cyclodextrinpolysaccharide-based, in situ-gelled system for ocular antifungal delivery, Beilstein Journal of Organic Chemistry, vol.10, pp.2903-2911, 2014.

R. J. Zoorob and D. Cender, A different look at corticosteroids, Am Fam Physician, vol.58, pp.443-450, 1998.

G. Behl, J. Iqbal, N. J. O'reilly, P. Mcloughlin, and L. Fitzhenry, Synthesis and Characterization of Poly(2-hydroxyethylmethacrylate) Contact Lenses Containing Chitosan Nanoparticles as an Ocular Delivery System for Dexamethasone Sodium Phosphate, Pharm. Res, vol.33, pp.1638-1648, 2016.

A. R. Djalilian, C. N. Nagineni, S. P. Mahesh, J. A. Smith, R. B. Nussenblatt et al., Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin, Cornea, vol.25, pp.709-714, 2006.

A. Fernández-ferreiro, J. Silva-rodríguez, F. J. Otero-espinar, M. González-barcia, M. J. Lamas et al.,

, Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations, Invest. Ophthalmol. Vis. Sci, vol.58, pp.772-780, 2017.

A. Castro-balado, C. Mondelo-garcía, M. González-barcia, I. Zarra-ferro, F. J. Otero-espinar et al., Fernández-Ferreiro, A. Ocular Biodistribution Studies Using Molecular Imaging, Pharmaceutics, p.237, 2019.

A. Luaces-rodríguez, R. Touriño-peralba, I. Alonso-rodríguez, X. García-otero, M. González-barcia et al., Preclinical characterization and clinical evaluation of tacrolimus eye drops

, European Journal of Pharmaceutical Sciences, vol.120, pp.152-161, 2018.

, International Conference on Harmonisation -Stability testing of new drug substances and products Q1A (R2), 2003.

P. Pisella, C. Baudoin, T. Hoang-xuan, and . Surface-oculaire, Rapport, 2015.

. Masson, , 2015.

J. S. Kelly, Topical ophthalmic drug administration: a practical guide, Br J Nurs, vol.3, pp.518-520, 1994.

U. B. Kompella, R. S. Kadam, and V. H. Lee, Recent advances in ophthalmic drug delivery, Ther Deliv, vol.1, pp.435-456, 2010.

A. F. Hanafy, A. M. Abdalla, T. K. Guda, K. E. Gabr, P. G. Royall et al., Ocular antiinflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self-assembled nanoparticles, Int J Nanomedicine, vol.14, pp.3679-3689, 2019.

S. Gause, K. Hsu, C. Shafor, P. Dixon, K. C. Powell et al., Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses, Adv Colloid Interface Sci, vol.233, pp.139-154, 2016.

M. M. Ibrahim, A. H. Abd-elgawad, O. A. Soliman, and M. M. Jablonski, Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma, Transl Vis Sci Technol, vol.4, p.12, 2015.

J. Ali, M. Fazil, M. Qumbar, N. Khan, and A. Ali, Colloidal drug delivery system: amplify the ocular delivery, Drug Deliv, vol.23, pp.710-726, 2016.

J. Araújo, E. Gonzalez, M. A. Egea, M. L. Garcia, and E. B. Souto, Nanomedicines for ocular NSAIDs: safety on drug delivery, Nanomedicine, vol.5, pp.394-401, 2009.

X. Gai, L. Cheng, T. Li, D. Liu, Y. Wang et al., In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen. AAPS PharmSciTech, vol.19, pp.700-709, 2018.

B. Lorenzo-veiga, H. H. Sigurdsson, and T. Loftsson, Nepafenac-Loaded Cyclodextrin/Polymer Nanoaggregates: A New Approach to Eye Drop Formulation. Materials (Basel) 2019, p.12

J. Shen, L. Gan, C. Zhu, X. Zhang, Y. Dong et al., Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved antiinflammation effect, Int J Pharm, vol.412, pp.115-122, 2011.

M. Jamard, T. Hoare, and H. Sheardown, Nanogels of methylcellulose hydrophobized with N-tertbutylacrylamide for ocular drug delivery, Drug Deliv Transl Res, vol.6, pp.648-659, 2016.

S. Patel, C. Garapati, P. Chowdhury, H. Gupta, J. Nesamony et al., Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application, J Ocul Pharmacol Ther, vol.31, pp.215-227, 2015.

R. Katara, S. Sachdeva, and D. K. Majumdar, Design, characterization, and evaluation of aceclofenacloaded Eudragit RS 100 nanoparticulate system for ocular delivery, Pharm Dev Technol, vol.24, pp.368-379, 2019.

P. Calvo, J. L. Vila-jato, and M. J. Alonso, Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers, International Journal of Pharmaceutics, vol.153, pp.41-50, 1997.

E. Gonzalez-mira, S. Nikoli?, A. C. Calpena, M. A. Egea, E. B. Souto et al., Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels, J Pharm Sci, vol.101, pp.707-725, 2012.

S. Swaminathan, P. R. Vavia, F. Trotta, and R. Cavalli, Nanosponges encapsulating dexamethasone for ocular delivery: formulation design, physicochemical characterization, safety and corneal permeability assessment, J Biomed Nanotechnol, vol.9, pp.998-1007, 2013.

J. B. Yaméogo, A. Gèze, L. Choisnard, J. Putaux, A. Gansané et al., Self-assembled biotransesterified cyclodextrins as Artemisinin nanocarriers -I: formulation, lyoavailability and in vitro antimalarial activity assessment, Eur J Pharm Biopharm, vol.80, pp.508-517, 2012.

L. Choisnard, A. Gèze, C. Vanhaverbeke, J. B. Yaméogo, J. Putaux et al., Physicochemical characterization of ?-, ?-, and ?cyclodextrins bioesterified with decanoate chains used as building blocks of colloidal nanoparticles, Biomacromolecules, vol.12, pp.3031-3038, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00619420

L. Choisnard, A. Gèze, J. Putaux, Y. Wong, and D. Wouessidjewe, Nanoparticles of betacyclodextrin esters obtained by self-assembling of biotransesterified beta-cyclodextrins, Biomacromolecules, vol.7, pp.515-520, 2006.

L. Choisnard, A. Gèze, B. G. Yaméogo, J. Putaux, and D. Wouessidjewe, Miscellaneous nanoaggregates made of beta-CD esters synthesised by an enzymatic pathway, Int J Pharm, vol.344, pp.26-32, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00384471

A. Gèze, L. Choisnard, J. Putaux, and D. Wouessidjewe, Colloidal systems made of biotransesterified ?, ? and ? cyclodextrins grafted with C10 alkyl chains, Materials Science, vol.29, pp.458-462, 2009.

J. B. Yaméogo, R. Mazet, D. Wouessidjewe, L. Choisnard, D. Godin-ribuot et al., Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic ?-cyclodextrin nanoparticles, Materials Science and Engineering, vol.2020, p.110281

Z. B. Akkus, I. Nazir, A. Jalil, M. Tribus, and A. Bernkop-schnürch, Zeta Potential Changing Polyphosphate Nanoparticles: A Promising Approach To Overcome the Mucus and Epithelial Barrier, Mol. Pharm, vol.16, pp.2817-2825, 2019.

M. M. Ibrahim, A. H. Abd-elgawad, O. A. Soliman, and M. M. Jablonski, Stability and Ocular Pharmacokinetics of Celecoxib-Loaded Nanoparticles Topical Ophthalmic Formulations, J Pharm Sci, vol.105, pp.3691-3701, 2016.

H. Gupta, M. Aqil, R. K. Khar, A. Ali, A. Bhatnagar et al., Nanoparticles laden in situ gel for sustained ocular drug delivery, J Pharm Bioallied Sci, vol.5, pp.162-165, 2013.

R. Mazet, L. Choisnard, D. Levilly, D. Wouessidjewe, and A. Gèze, Investigation of Combined Cyclodextrin and Hydrogel Formulation for Ocular Delivery of Dexamethasone Acetate by Means of Experimental Designs, Pharmaceutics, p.10, 2018.

J. B. Yaméogo, A. Gèze, L. Choisnard, J. Putaux, R. Mazet et al., Self-assembled biotransesterified cyclodextrins as potential Artemisinin nanocarriers. II: In vitro behavior toward the immune system and in vivo biodistribution assessment of unloaded nanoparticles, Eur J Pharm Biopharm, 2014.

A. Graça, L. M. Gonçalves, S. Raposo, H. M. Ribeiro, and J. Marto, Useful In Vitro Techniques to Evaluate the Mucoadhesive Properties of Hyaluronic Acid-Based Ocular Delivery Systems, Pharmaceutics, p.10, 2018.

M. M. Silva, R. Calado, J. Marto, A. Bettencourt, A. J. Almeida et al., Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration, p.15, 2017.

S. B. Da-silva, D. Ferreira, M. Pintado, and B. Sarmento, Chitosan-based nanoparticles for rosmarinic acid ocular delivery--In vitro tests, Int. J. Biol. Macromol, vol.84, pp.112-120, 2016.

S. Rönkkö, K. Vellonen, K. Järvinen, E. Toropainen, and A. Urtti, Human corneal cell culture models for drug toxicity studies, Drug Deliv Transl Res, vol.6, pp.660-675, 2016.

Y. Wen, J. Ban, Z. Mo, Y. Zhang, P. An et al., A potential nanoparticle-loaded in situ gel for enhanced and sustained ophthalmic delivery of dexamethasone, Nanotechnology, vol.29, p.425101, 2018.

N. R. Council, Guide for the Care and Use of Laboratory Animals: Eighth Edition, 2010.

, Committee for the Update of the Guide for the Care and Use of Laboratory Animals Guide for the Care and Use of Laboratory Animals; The National Academies Collection: Reports funded by National Institutes of Health, 2011.

Y. Zhang, M. Huo, J. Zhou, S. Xie, and . Pksolver, An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel, Computer Methods and Programs in Biomedicine, vol.99, pp.306-314, 2010.

, European Phramacopoeia; 9, 2019.

R. Salzillo, C. Schiraldi, L. Corsuto, A. D'agostino, R. Filosa et al., Optimization of hyaluronan-based eye drop formulations, Carbohydrate Polymers, vol.153, pp.275-283, 2016.

T. Irimia, M. Ghica, L. Popa, V. Anu?a, A. Arsene et al., Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems, Polymers, vol.10, p.1221, 2018.

H. Zhu and A. Chauhan, Effect of viscosity on tear drainage and ocular residence time, Optom Vis Sci, vol.85, pp.715-725, 2008.

I. Zaki, P. Fitzgerald, J. G. Hardy, and C. G. Wilson, A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man, J. Pharm. Pharmacol, vol.38, pp.463-466, 1986.

N. M. Davies, Biopharmaceutical considerations in topical ocular drug delivery, Clin. Exp. Pharmacol. Physiol, vol.27, pp.558-562, 2000.

M. Ruponen and A. Urtti, Undefined role of mucus as a barrier in ocular drug delivery, Eur J Pharm Biopharm, vol.96, pp.442-446, 2015.

J. Shen, Y. Wang, Q. Ping, Y. Xiao, and X. Huang, Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery, J Control Release, vol.137, pp.217-223, 2009.

F. Madsen, K. Eberth, and J. D. Smart, A rheological examination of the mucoadhesive/mucus interaction: the effect of mucoadhesive type and concentration, J Control Release, vol.50, pp.167-178, 1998.

G. B. Romero, C. M. Keck, R. H. Müller, and N. A. Bou-chacra, Development of cationic nanocrystals for ocular delivery, Eur J Pharm Biopharm, vol.107, pp.215-222, 2016.

, OECD Guideline for the testing of chemicals -Short time exposure in vitro test method, p.19, 2018.

F. A. Barile, Validating and troubleshooting ocular in vitro toxicology tests, J Pharmacol Toxicol Methods, vol.61, pp.136-145, 2010.

R. J. Zoorob and D. Cender, A different look at corticosteroids, Am Fam Physician, vol.58, pp.443-450, 1998.

G. Behl, J. Iqbal, N. J. O'reilly, P. Mcloughlin, and L. Fitzhenry, Synthesis and Characterization of Poly(2-hydroxyethylmethacrylate) Contact Lenses Containing Chitosan Nanoparticles as an Ocular Delivery System for Dexamethasone Sodium Phosphate, Pharm. Res, vol.33, pp.1638-1648, 2016.

A. R. Djalilian, C. N. Nagineni, S. P. Mahesh, J. A. Smith, R. B. Nussenblatt et al., Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin, Cornea, vol.25, pp.709-714, 2006.

, cyclodextrine ont permis de multiplier par un facteur 500 et 1550 la solubilité apparente à 25 °C de la DXMa, soit 10 mg/mL de DXMa solubilisée par l'HP?CD et 30 mg/mL par l'HP?CD

, Impact des cyclodextrines : ?CD, ?CD, SBE?CD, HP?CD et HP?CD sur la solubilité apparente de l'acétate de dexaméthasone (DXMa) dans l, p.25

, Les constantes d'associations des deux complexes les plus intéressants du point de vue de l'augmentation de la solubilité, DXMa/ HP?CD et DXMa/ HP?CD, ont été calculées par la méthode de diagramme de solubilité et par, CLHP en assumant une stoechiométrie, vol.1, issue.9, p.1

, Les efficacités de complexation (Complexation Efficiency, CE) ont également été calculées

, Il apparait clairement que l'affinité de la DXMa pour la cavité de la cyclodextrine est plus forte pour l'HP?CD que pour l'HP?CD, Les résultats sont regroupés dans le Tableau 5

D. Achouri, K. Alhanout, P. Piccerelle, and V. Andrieu, Recent advances in ocular drug delivery, Drug Dev Ind Pharm, vol.39, pp.1599-1617, 2013.

S. Yeh, L. J. Faia, and R. B. Nussenblatt, Advances in the diagnosis and immunotherapy for ocular inflammatory disease, Semin Immunopathol, vol.30, pp.145-164, 2008.

U. B. Kompella, R. S. Kadam, and V. H. Lee, Recent advances in ophthalmic drug delivery, Ther Deliv, vol.1, pp.435-456, 2010.

, ANSM Résumé des caractéristiques produit -DEXAFREE 1mg/mL, 2019.

S. Göktürk, E. Çal??kan, R. Y. Talman, and U. Var, A Study on Solubilization of Poorly Soluble Drugs by Cyclodextrins and Micelles: Complexation and Binding Characteristics of Sulfamethoxazole and Trimethoprim, ScientificWorldJournal, p.718791, 2012.

Y. Shi, W. Porter, T. Merdan, and L. C. Li, Recent advances in intravenous delivery of poorly watersoluble compounds, Expert Opinion on Drug Delivery, vol.6, pp.1261-1282, 2009.

P. Jansook, N. Ogawa, and T. Loftsson, Cyclodextrins: structure, physicochemical properties and pharmaceutical applications, Int J Pharm, vol.535, pp.272-284, 2018.

C. Muankaew and T. Loftsson, Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery, Basic Clin Pharmacol Toxicol, vol.122, pp.46-55, 2018.

C. Ravelet, A. Geze, A. Villet, C. Grosset, A. Ravel et al., Chromatographic determination of the association constants between nimesulide and native and modified beta-cyclodextrins, J Pharm Biomed Anal, vol.29, pp.425-430, 2002.

E. Stefánsson and T. Loftsson, Cyclodextrins in Eye Drop Formulations, J Incl Phenom Macrocycl Chem, vol.44, pp.23-27, 2002.

V. Chédru-legros, M. Fines-guyon, A. Chérel, A. Perdriel, F. Albessard et al.,

, J Fr Ophtalmol, vol.30, pp.807-813, 2007.

J. Wang, F. Zhao, R. Liu, J. Chen, Q. Zhang et al., Novel cationic lipid nanoparticles as an ophthalmic delivery system for multicomponent drugs: development, characterization, in vitro permeation, in vivo pharmacokinetic, and molecular dynamics studies, Int J Nanomedicine, vol.12, pp.8115-8127, 2017.

R. Mazet, L. Choisnard, D. Levilly, D. Wouessidjewe, and A. Gèze, Investigation of Combined Cyclodextrin and Hydrogel Formulation for Ocular Delivery of Dexamethasone Acetate by Means of Experimental Designs, Pharmaceutics, p.10, 2018.

R. Liu, L. Sun, S. Fang, S. Wang, J. Chen et al., Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin: development, characterization, in vitro permeation and in vivo pharmacokinetic studies, Pharm Dev Technol, vol.21, pp.576-582, 2016.

C. Di-tommaso, J. Bourges, F. Valamanesh, G. Trubitsyn, A. Torriglia et al., Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies, Eur J Pharm Biopharm, vol.81, pp.257-264, 2012.

L. Luo, J. Yang, Y. Oh, M. J. Hartsock, S. Xia et al., Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis, Journal of Controlled Release, vol.296, pp.68-80, 2019.

C. Di-tommaso, F. Behar-cohen, R. Gurny, and M. Möller, Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye, Annales Pharmaceutiques Françaises, vol.69, pp.116-123, 2011.

L. Choisnard, A. Gèze, B. G. Yaméogo, J. Putaux, and D. Wouessidjewe, Miscellaneous nanoaggregates made of beta-CD esters synthesised by an enzymatic pathway, Int J Pharm, vol.344, pp.26-32, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00384471

J. Putaux, C. Lancelon-pin, F. Legrand, M. Pastrello, L. Choisnard et al., Assembly of Amphiphilic Biotransesterified ?-Cyclodextrins: Supramolecular Structure of Nanoparticles and Surface Properties, vol.33, pp.7917-7928, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02106206

P. Perret, S. Bacot, A. Gèze, A. Gentil-dit-maurin, M. Debiossat et al., Biodistribution and preliminary toxicity studies of nanoparticles made of Biotransesterified ?-cyclodextrins and PEGylated phospholipids, Mater Sci Eng C Mater Biol Appl, vol.85, pp.7-17, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02106169

J. B. Yaméogo, A. Gèze, L. Choisnard, J. Putaux, R. Mazet et al., Self-assembled biotransesterified cyclodextrins as potential Artemisinin nanocarriers. II: In vitro behavior toward the immune system and in vivo biodistribution assessment of unloaded nanoparticles, Eur J Pharm Biopharm, 2014.

J. B. Yaméogo, R. Mazet, D. Wouessidjewe, L. Choisnard, D. Godin-ribuot et al., Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic ?-cyclodextrin nanoparticles, Materials Science and Engineering, vol.2020, p.110281

R. Salzillo, C. Schiraldi, L. Corsuto, A. D'agostino, R. Filosa et al., Optimization of hyaluronan-based eye drop formulations, Carbohydrate Polymers, vol.153, pp.275-283, 2016.

I. Zaki, P. Fitzgerald, J. G. Hardy, and C. G. Wilson, A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man, J. Pharm. Pharmacol, vol.38, pp.463-466, 1986.

, OECD Guideline for the testing of chemicals -Short time exposure in vitro test method, p.19, 2018.

C. Baudouin, A. Labbé, H. Liang, A. Pauly, and F. Brignole-baudouin, Preservatives in eyedrops: The good, the bad and the ugly, Progress in Retinal and Eye Research, vol.29, pp.312-334, 2010.

F. A. Barile, Validating and troubleshooting ocular in vitro toxicology tests, J Pharmacol Toxicol Methods, vol.61, pp.136-145, 2010.

A. R. Djalilian, C. N. Nagineni, S. P. Mahesh, J. A. Smith, R. B. Nussenblatt et al., Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin, Cornea, vol.25, pp.709-714, 2006.

E. Voyron, Formulation de collyre de ciclosporine à 2 %, 2016.

D. R. Janagam, L. Wu, and T. L. Lowe, Nanoparticles for drug delivery to the anterior segment of the eye, Advanced Drug Delivery Reviews, vol.122, pp.31-64, 2017.

R. Mazet, , 2012.